GlassScriptPhysician profile
Kenneth L Justice
NPI 1891747853
$4,643.94
in general payments reported to CMS, 2019-2025
29 companies · $666 in 2025
The $666 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $520 · 2021: $574 · 2022: $767 · 2023: $1,130 · 2024: $818 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.55 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $693.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $425.57 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $410.24 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.94 | 2019-2024 | Ofev, Jardiance |
| Pfizer INC. | $341.10 | 2019-2025 | |
| Abbvie INC. | $327.79 | 2022-2025 | |
| Dexcom, INC. | $241.52 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $201.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $194.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $183.29 | 2021-2025 | |
| Lilly USA, LLC | $172.00 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $160.21 | 2023-2024 | Veozah |
| Glaxosmithkline, LLC. | $152.42 | 2020-2025 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $100.91 | 2022-2025 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $99.98 | 2020-2024 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $95.76 | 2019-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $86.79 | 2024-2025 | Wavewriter Alpha Prime 16, Bodyguardian |
| Abbott Laboratories | $65.80 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.80 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $44.88 | 2020-2021 | |
| Daiichi Sankyo INC. | $42.29 | 2022-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $37.74 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $23.52 | 2021 | |
| Dynavax Technologies Corporation | $17.97 | 2024 | Heplisav-B |
| Tandem Diabetes Care, INC. | $16.91 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Biohaven Pharmaceuticals, INC. | $14.31 | 2021 | |
| Medtronic, INC. | $14.28 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.53 | 2022 | |
| Allergan, INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Justice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.